Some studies have shown that metformin can improve liver function modestly and transiently decrease AST and ALT levels but has no histological benefit in NASH patients with steatosis, fibrosis, and inflammation [109]. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatohepatitis.